Weight loss Obesity - Search News

Ozempic vs. Metformin For Weight Loss

Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Newsweek on MSN · 3d

New Discovery Promises Weight Loss Without Ozempic's Side Effects

Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of semaglutide.

New York Post on MSN · 2d

We went blind after using weight-loss drugs like Ozempic and Mounjaro

I had no idea this could happen. I wouldn’t have done it,” New Jersey-based former Mounjaro user James Norris, who is now visually impaired, told The Post

AOL · 2d

Ozempic vs Metformin For Weight Loss: Which Is Best for Me?

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all these options stack up.

Interesting Engineering on MSN · 3d

AI finds natural peptide that matches Ozempic’s weight loss power without side effects

This new molecule, BRP, appears to suppress appetite and promote weight loss without some unpleasant side effects of semaglutide, including nausea and constipation. Professor Katr

Novo Nordisk, obesity and Gain

The Wall Street Journal · 1h

Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in rival Eli Lilly also sold off. Find out more:

Reuters on MSN · 11h

Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector

Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over Novo in the weight-loss drugs market.

Barron's on MSN · 10h

Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

2hon MSN

Who can get weight loss drugs on the NHS in Scotland?

Medications like Mounjaro and Wegovy have been hailed as "game changers" for tackling obesity.

5hon MSN

Fitness Coach Explains Why She Was Labeled 'Obese' for Years

"My doctor labelled me as 'overweight' and borderline 'obese.' The doctor barely looked at me before making that assessment," ...

8hon MSN

The State of Weight Loss Drugs

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

MPR7h

Significant Weight Loss Observed With CagriSema in REDEFINE 2 Trial

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

2don MSN

Weight-loss drug battle: Who are the latest players involved

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Devdiscourse4h

Eli Lilly Expands Horizons: Launching Weight-Loss Drug in Emerging Markets

Eli Lilly is set to launch its popular weight-loss drug in emerging markets, including India, Brazil, and Mexico, by mid-2025 ...

10h

This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity ...

Hosted on MSN3d

10 of the biggest weight loss myths, according to an obesity medicine expert

One quick online search or scroll through social media and you'll find an endless amount of weight loss advice. But it's hard ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results